Announced details
Treatment of fatty liver disease and nonalcoholic steatohepatitis
Joint applicants for the patent
Osaka University and Niigata University. Location, representative, business activities, capital and year established: Not disclosed
Application number: 2021466375; registration (publication) number: not yet determined; validity period: Not disclosed
There will be no impact on full-year results for the fiscal year ending July 2027. If any matter requiring disclosure arises, it will be disclosed promptly
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Regenerative medicine drug® redasemtide (HMGB1 fragment peptide), S-005151 |
| Counterparty | Osaka University and Niigata University |
| Counterparty overview | Osaka University and Niigata University. Location, representative, business activities, capital and year established: Not disclosed |
| Relationship with the Company | Joint applicants for the patent |
| Applicable area | Treatment of fatty liver disease and nonalcoholic steatohepatitis |
| Registration number and expiry date | Application number: 2021466375; registration (publication) number: not yet determined; validity period: Not disclosed |
| Impact on Business Performance | There will be no impact on full-year results for the fiscal year ending July 2027. If any matter requiring disclosure arises, it will be disclosed promptly |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To expand the indications for redasemtide and secure the possibility of developing treatments for fatty liver disease and non-alcoholic steatohepatitis in Australia.